Results 201 to 210 of about 121,777 (350)

One-year intravenous immunoglobulin replacement therapy: efficacy in reducing hospital admissions in pediatric patients with Inborn Errors of Immunity

, 2021
Karina Mescouto de Melo, Lucas Macedo Alves, Cláudia França Cavalcante Valente, Fabíola Scancetti Tavares   +3 more
openalex   +1 more source

Use of Human Intravenous Immunoglobulin Therapy in Two Dogs with Non-Neoplastic Bone Marrow Disorders Refractory to Immunosuppressive Therapy. [PDF]

Vet Sci
Kim EJ, Han HJ.
europepmc   +1 more source

A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better? [PDF]

Cardiovasc Ther, 2021
Li W, He X, Zhang L, Wang Z, Wang Y, Lin H, Yuan J, Xie X, Qin Y, Huang P.   +9 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study. [PDF]

BMC Pulm Med, 2021
Ali HS, Elshafei MS, Saad MO, Mitwally HA, Al Wraidat M, Aroos A, Shaikh N, Ananthegowda DC, Abdelaty MA, George S, Nashwan AJ, Mohamed AS, Khatib MY.   +12 more
europepmc   +2 more sources

Plasma levels of Human Granulocytic Elastase-alpha-Proteinase Inhibitor Complex (E-alpha1PI) in Leukemia [PDF]

, 1984
Hiller, E., Jochum, Marianne
core  

Successful intravenous immunoglobulin therapy in paraneoplastic pemphigus associated with hepatocellular carcinoma. [PDF]

An Bras Dermatol
Ramos J, Afonso C, Roda Â, Fonseca C.
europepmc   +1 more source

Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: A case report. [PDF]

Front Immunol, 2022
Zhang W, Jiao Y, Jiao J, Jin M, Peng D.
europepmc   +1 more source

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to ...
Iek Leng Cheng, Zhong Hui Huang, Austen Worth, Claire Booth, Joseph F. Standing   +4 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source